1
|
Halil MG, Demirkan K, Doganay M, Cengiz C, Gunduz M, Abbasoglu O. Accreditation of nutrition support teams: A new initiative by the Turkish Society of Clinical Enteral & Parenteral Nutrition. Nutrition 2023; 114:112112. [PMID: 37450961 DOI: 10.1016/j.nut.2023.112112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 05/20/2023] [Accepted: 05/30/2023] [Indexed: 07/18/2023]
Abstract
OBJECTIVES Accreditation is a process to evaluate compliance of an institution or organization with predetermined performance standards, focusing on achieving continuous improvement strategies and optimal quality standards and motivating the accredited organization to do so. There is no established accreditation program for nutrition support teams (NSTs) at national and international levels. In order to increase the standards of NSTs, developing an accreditation program is being planned by the Turkish Society of Clinical Enteral & Parenteral Nutrition (KEPAN). METHODS Accreditation standards were developed by a study group under the organization of KEPAN. Minimum standards for composition, qualifications, physical requirements, workflow charts, medical records, and both patient and health care providers' safety measures in NSTs were specified. These standards were uploaded to a computer program, and the necessary infrastructure for a web-based management of accreditation processes was developed. RESULTS An organization applying for accreditation should fill in the application form on KEPAN website electronically. Eligibility criteria for accreditation include number of NST members, physical environment, patient monitoring requirements, research, and training. A total of 22 standards are surveyed under 13 sections. These standards contain 61 criteria. To be accredited, each of 22 standards must score >70 and each of 13 sections must score >80. CONCLUSIONS In order to increase the quality of nutritional care and improve patient outcomes, an accreditation program has been developed. This program principally sets the basic standards, organizational scheme, and responsibilities of NSTs.
Collapse
Affiliation(s)
- Meltem Gulhan Halil
- Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
| | - Kutay Demirkan
- Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
| | - Mutlu Doganay
- Department of General Surgery, Faculty of Medicine, Ankara Bilkent City Hospital, University of Health Sciences, Ankara, Turkey
| | - Canan Cengiz
- Health Institutes of Turkey, Turkish Health Care Quality and Accreditation Institute, Ankara, Turkey
| | - Murat Gunduz
- Department of Anesthesiology and Reanimation, Faculty of Medicine, Cukurova University, Adana, Turkey
| | - Osman Abbasoglu
- Clinical Nutrition Master's Program, Hacettepe University, Ankara, Turkey
| |
Collapse
|
4
|
Saghatchian M, Thonon F, Boomsma F, Hummel H, Koot B, Harrison C, Rajan A, de Valeriola D, Otter R, Laranja Pontes J, Lombardo C, McGrath E, Ringborg U, Tursz T, van Harten W. Pioneering quality assessment in European cancer centers: a data analysis of the organization for European cancer institutes accreditation and designation program. J Oncol Pract 2014; 10:e342-9. [PMID: 25118210 DOI: 10.1200/jop.2013.001331] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE In order to improve the quality of care in Cancer Centers (CC) and designate Comprehensive Cancer Centers (CCCs), the Organization for European Cancer Institutes (OECI) launched an Accreditation and Designation (A&D) program. The program facilitates the collection of defined data and the assessment of cancer center quality. This study analyzes the results of the first 10 European centers that entered the program. METHODS The assessment included 927 items divided across qualitative and quantitative questionnaires. Data collected during self-assessment and peer-review from the 10 first participating centers were combined in a database for comparative analysis using simple statistics. Quantitative and qualitative results were validated by auditors during the peer review visits. RESULTS Volumes of various functions and activities dedicated to care, research, and education varied widely among centers. There were no significant differences in resources for radiology, radiotherapy, pathologic diagnostic, and surgery. Differences were observed in the use of clinical pathways but not for the practices of holding multidisciplinary team meetings and conforming to guidelines. Regarding human resources, main differences were in the composition and number of supportive care and research staff. All 10 centers applied as CCCs; five obtained the label, and five were designated as CCs. CONCLUSION The OECI A&D program allows comparisons between centers with regard to management, research, care, education, and designation as CCs or CCCs. Through the peer review system, recommendations for improvements are given. Assessing the added value of the program, as well as research and patient treatment outcomes, is the next step.
Collapse
Affiliation(s)
- Mahasti Saghatchian
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Frédérique Thonon
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Femke Boomsma
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Henk Hummel
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Bert Koot
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Chris Harrison
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Abinaya Rajan
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Dominique de Valeriola
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Renée Otter
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - José Laranja Pontes
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Claudio Lombardo
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Eoin McGrath
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Ulrik Ringborg
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Thomas Tursz
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| | - Wim van Harten
- Institut Gustave Roussy, Villejuif, France; Integraal Kankercentruum Nederland, Grongingen; Compusense, Voorhout; Netherlands Cancer Institute, Amsterdam, the Netherlands; Imperial College Healthcare NHS Trust, London, United Kingdom; Institut Jules Bordet; Organisation of European Cancer Institutes, Brussels, Belgium; Instituto Português de Oncologia do Porto, Porto, Portugal; European Group for Blood and Marrow Transplantation, Barcelona, Spain; and Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|